- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01959984
Study on the Comparison Between"Standard Noodles" and Traditional Carbohydrates in the Diagnosis of Diabetes Mellitus.
The object of this study is to compare "100g Standard Noodles " with traditional carbohydrates including 75g glucose solution in 300ml water and 100g steamed bread in the diagnosis of diabetes mellitus.
In this study, we will compare the different effects of "100g Standard Noodles Tolerance Test"and "75g Oral Glucose Tolerance Test"on plasma glucose, insulin, c- peptide level and the relevant hormones level including glucagon-like peptide-1( GLP-1) and glucagon. Besides, in part of the subjects, the difference between "100g Steamed Bread Tolerance Test", "100g Standard Noodles Tolerance Test" and "75g Oral Glucose Tolerance Test" will be further evaluated.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Shanghai
-
Shanghai, Shanghai, China, 200021
- Shanghai Jiao Tong University School of Medicine
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Inclusion Criteria:
For healthy subjects:
- Between 16-70 years old.
- No weight fluctuation greater than 5% within 3 months.
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures .
For subjects with impaired glucose regulation(IGR):
- Between 16-70 years old.
- Impaired fasting glucose(IFG):6.1mM(109mg/ml)≤fasting plasma glucose(FPG)<7.0mM(126mg/ml),or impaired glucose tolerance(IGT):7.8mM(140mg/ml)≤2h plasma glucose(2hPG)<11.1mM(200mg/dl),or both.
- No weight fluctuation greater than 5% within3 months.
- Keep stable antidiabetic therapy for at least 2 months.
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures .
For subjects with type 2 diabetes mellitus(T2DM):
- Between 16-70 years old.
- T2DM:diabetic symptoms plus random blood glucose(RBG)≥11.1mM,or FPG ≥7.0mM(126mg/dl),or 2hPG ≥11.1mM(200mg/dl).
- No weight fluctuation greater than 5% within 3 months.
- Keep stable antidiabetic therapy at least for 2 months.
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
For subjects with type 1 diabetes mellitus(T1DM):
- Between 16-70 years old.
- T1DM:diabetic symptoms plus RBG≥11.1mM,or FPG ≥7.0mM(126mg/dl),or 2hPG ≥11.1mM(200mg/dl).
- Present at least one positive antibody of β cell including ICA,IAA,GADA,IA-2A and IA-2βA.
- No weight fluctuation greater than 5% within 3 months.
- Keep stable antidiabetic therapy for at least 2 months.
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
Exclusion Criteria:
For healthy subjects:
- Be diagnosed with diabetes or IGR in late 3 months.
- With any significant medical condition,laboratory abnormality,or psychiatric disorders that will prevent the subject from participating in the study.
- Any medical or surgical conditions possibly affecting the experiment result.
- Participated in a clinical study involving administration of medication within 90 days.
- Donated blood or plasma or had any other significant blood loss within 2 months.
- Any clinically significant allergic diseases.
- Recently drug or alcohol abuse(>35unit/week,1unit=8 g alcohol@1 standard drink@250ml beer@140ml wine@25ml strong alcohol drink like whiskey.)
- Smokers or users of other tobacco products in the 3 months prior to screening.
For IGR and DM:
- History of pancreatic diseases such as pancreatic cancer or pancreatitis.
- Suffered from acute complications such as diabetic ketoacidosis and hyperosmolar coma within 3 months.
- With any significant medical condition,laboratory abnormality,or psychiatric disorders that will prevent the subject from participating in the study.
- Malignant tumor.
- Being allergic to experiment arms.
- Recently drug or alcohol abuse(>35unit/week,1unit=8 g alcohol@1 standard drink@250ml beer@140ml wine@25ml strong alcohol drink like whiskey.)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: 100g Standard Noodles
|
Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
|
|
Experimenteel: 75g Oral Glucose
|
Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The plasma glucose level.
Tijdsspanne: 12 months
|
The primary outcome measures the plasma glucose level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
|
The insulin level.
Tijdsspanne: 12 months
|
The primary outcome measures the insulin level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
|
The c-peptide level.
Tijdsspanne: 12 months
|
The primary outcome measures the c-peptide level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The GLP-1 level.
Tijdsspanne: 12months
|
The outcome measures of the GLP-1 level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12months
|
|
The Glucagon level.
Tijdsspanne: 12 months
|
The outcome measures of the glucagon level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
|
The other relevant incretin hormones levels.
Tijdsspanne: 12 months
|
The outcome measures of the relevant incretin hormones level at 0min,30min,60min,120min,180min during "75g Oral Glucose Tolerance Test" and "100g Standard Noodles Tolerance Test" .
|
12 months
|
|
The plasma glucose, insulin, c-peptide and relevant incretin hormones level during "75g Oral Glucose Tolerance Test", "100g Standard Noodles Tolerance Test" and "100g Steamed Bread Tolerance Test".
Tijdsspanne: 12 months
|
12 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Safety
Tijdsspanne: 12 months
|
Document the frequency and extent of side-effects.
|
12 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Guang Ning, MD,PHD, Shanghai Jiao Tong University School of Medicine
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CCEMD018
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .